-
Uncategorized2 months ago
Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns
Right after the FDA flagged safety concerns for Eli Lilly’s newly approved obesity pill, the pharma posted diabetes data demonstrating a clean safety profile and revealed...
-
Uncategorized2 months ago
Can Europe turn world-class science into world-class scale?
Despite exceptional regional hubs and research strength, investors say Europe still needs more integrated incubators, smarter regulation and broader pools of patient capital to keep breakthrough...
-
Uncategorized2 months ago
RyghtAI launches clinical site search engine to aid drug developers, CROs with trial design
Clinical site selection platform RyghtAI has launched a search engine designed to give drug developers and contract research organizations access to a comprehensive database of clinical...
-
Uncategorized2 months ago
Obesity’s explosive growth continues as Q1 deals exceed total 2025 value
Commitments in obesity- and diabetes-focused deals reached $22 billion in the first quarter of 2026—already eclipsing last year’s total of $20.3 billion, according to a new...
-
Uncategorized2 months agoSTAT+: Pharmalittle: We’re reading about a review of Alzheimer’s drugs, FDA interest in compounded peptides, and more
Top of the morning to you. And a fine one it is here at the Pharmalot campus, where the official mascots are snoozing away thanks to...
-
Uncategorized2 months ago
Revolution doubles stock offering target to $2B following pancreatic cancer win
After Revolution Medicines’ drug candidate doubled survival in a Phase 3 pancreatic cancer study, the biotech is hoping to attract more investor money, with new plans...
-
Uncategorized2 months ago
Novartis CEO joins Anthropic board, embedding AI in the heart of biopharma
In recent months, Anthropic has been building more and more ties with the biopharma industry, including partnerships with Big Pharma companies such as Sanofi, Novo Nordisk...
-
Uncategorized2 months agoThe mental health parity gap is gaping
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. What do you eat in the...
-
Uncategorized2 months ago
Lilly’s obesity pill heads for diabetes filing after heart risk trial
Eli Lilly’s recently approved obesity pill Foundayo cut the risk of cardiovascular events like heart attack and stroke by 16% versus a form of insulin, new...
-
Uncategorized2 months agoSTAT+: Roche to launch another Elevidys trial, with eyes on European approval
In an attempt to win European approval for the controversial medicine, Roche said Thursday it would run another trial of the Duchenne muscular dystrophy gene therapy...
Amgen shores up Tavneos’ FDA defense with Duke data analysis
